nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Paclitaxel—kidney cancer	0.147	0.228	CbGbCtD
Olmesartan—SLCO1B1—Pazopanib—kidney cancer	0.131	0.203	CbGbCtD
Olmesartan—ABCC2—Paclitaxel—kidney cancer	0.0754	0.117	CbGbCtD
Olmesartan—ABCC2—Sorafenib—kidney cancer	0.067	0.103	CbGbCtD
Olmesartan—ABCC2—Vinblastine—kidney cancer	0.0661	0.102	CbGbCtD
Olmesartan—ABCC2—Vincristine—kidney cancer	0.065	0.1	CbGbCtD
Olmesartan—ABCC2—Sunitinib—kidney cancer	0.0543	0.0839	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—kidney cancer	0.0406	0.0628	CbGbCtD
Olmesartan—AGTR1—nephron—kidney cancer	0.0111	0.345	CbGeAlD
Olmesartan—Irbesartan—JUN—kidney cancer	0.00256	0.505	CrCbGaD
Olmesartan—AGTR1—nephron tubule—kidney cancer	0.0024	0.0745	CbGeAlD
Olmesartan—AGTR1—renal system—kidney cancer	0.00218	0.0677	CbGeAlD
Olmesartan—AGTR1—kidney—kidney cancer	0.00211	0.0654	CbGeAlD
Olmesartan—SLCO1B1—renal system—kidney cancer	0.00208	0.0645	CbGeAlD
Olmesartan—AGTR1—cortex of kidney—kidney cancer	0.00206	0.0637	CbGeAlD
Olmesartan—SLCO1B1—kidney—kidney cancer	0.00201	0.0624	CbGeAlD
Olmesartan—AGTR1—cardiac atrium—kidney cancer	0.00196	0.0606	CbGeAlD
Olmesartan—ABCC2—nephron tubule—kidney cancer	0.00174	0.0538	CbGeAlD
Olmesartan—ABCC2—renal system—kidney cancer	0.00158	0.0489	CbGeAlD
Olmesartan—ABCC2—kidney—kidney cancer	0.00153	0.0473	CbGeAlD
Olmesartan—ABCC2—cortex of kidney—kidney cancer	0.00149	0.0461	CbGeAlD
Olmesartan—AGTR1—Allograft Rejection—HARS—kidney cancer	0.000821	0.0531	CbGpPWpGaD
Olmesartan—Candesartan—PTGS1—kidney cancer	0.000737	0.146	CrCbGaD
Olmesartan—Irbesartan—PTGS1—kidney cancer	0.000737	0.146	CrCbGaD
Olmesartan—ABCC2—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000677	0.0437	CbGpPWpGaD
Olmesartan—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000635	0.041	CbGpPWpGaD
Olmesartan—ABCC2—Irinotecan Pathway—BCHE—kidney cancer	0.000574	0.0371	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—BCHE—kidney cancer	0.000539	0.0348	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—LRRK2—kidney cancer	0.000472	0.0305	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—GRB7—kidney cancer	0.00045	0.0291	CbGpPWpGaD
Olmesartan—Telmisartan—ABCB1—kidney cancer	0.000445	0.0878	CrCbGaD
Olmesartan—AGTR1—Arf6 trafficking events—CTNNA1—kidney cancer	0.000398	0.0257	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.00037	0.0239	CbGpPWpGaD
Olmesartan—Candesartan—ABCB1—kidney cancer	0.000358	0.0707	CrCbGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000348	0.0225	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PAK1—kidney cancer	0.000315	0.0203	CbGpPWpGaD
Olmesartan—ABCC2—Irinotecan Pathway—APC—kidney cancer	0.000312	0.0201	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—APC—kidney cancer	0.000293	0.0189	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL13—kidney cancer	0.000269	0.0174	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—MET—kidney cancer	0.000255	0.0165	CbGpPWpGaD
Olmesartan—Losartan—ABCB1—kidney cancer	0.000231	0.0456	CrCbGaD
Olmesartan—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000223	0.0144	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000213	0.0137	CbGpPWpGaD
Olmesartan—ABCC2—ABC-family proteins mediated transport—ABCB1—kidney cancer	0.000203	0.0131	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 trafficking events—CDH1—kidney cancer	0.000174	0.0113	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—ABCB1—kidney cancer	0.000174	0.0112	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—SLC5A3—kidney cancer	0.000165	0.0106	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000147	0.000489	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Vincristine—kidney cancer	0.000147	0.000489	CcSEcCtD
Olmesartan—Fatigue—Vincristine—kidney cancer	0.000147	0.000488	CcSEcCtD
Olmesartan—Rash—Erlotinib—kidney cancer	0.000146	0.000488	CcSEcCtD
Olmesartan—Dermatitis—Erlotinib—kidney cancer	0.000146	0.000487	CcSEcCtD
Olmesartan—Palpitations—Paclitaxel—kidney cancer	0.000146	0.000487	CcSEcCtD
Olmesartan—Hyponatraemia—Doxorubicin—kidney cancer	0.000146	0.000486	CcSEcCtD
Olmesartan—Insomnia—Gemcitabine—kidney cancer	0.000146	0.000486	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—ITPR2—kidney cancer	0.000146	0.0094	CbGpPWpGaD
Olmesartan—Headache—Erlotinib—kidney cancer	0.000145	0.000484	CcSEcCtD
Olmesartan—Loss of consciousness—Paclitaxel—kidney cancer	0.000145	0.000484	CcSEcCtD
Olmesartan—Pain—Vincristine—kidney cancer	0.000145	0.000484	CcSEcCtD
Olmesartan—Constipation—Vincristine—kidney cancer	0.000145	0.000484	CcSEcCtD
Olmesartan—Pain in extremity—Doxorubicin—kidney cancer	0.000145	0.000484	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000145	0.00938	CbGpPWpGaD
Olmesartan—Cough—Paclitaxel—kidney cancer	0.000144	0.000481	CcSEcCtD
Olmesartan—Asthenia—Sunitinib—kidney cancer	0.000144	0.00048	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—KEAP1—kidney cancer	0.000144	0.0093	CbGpPWpGaD
Olmesartan—Nausea—Vinblastine—kidney cancer	0.000143	0.000478	CcSEcCtD
Olmesartan—Nausea—Everolimus—kidney cancer	0.000143	0.000476	CcSEcCtD
Olmesartan—Diarrhoea—Sorafenib—kidney cancer	0.000143	0.000476	CcSEcCtD
Olmesartan—Pruritus—Sunitinib—kidney cancer	0.000142	0.000474	CcSEcCtD
Olmesartan—Angiopathy—Capecitabine—kidney cancer	0.000141	0.000471	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RELA—kidney cancer	0.000141	0.0091	CbGpPWpGaD
Olmesartan—Chest pain—Paclitaxel—kidney cancer	0.000141	0.000469	CcSEcCtD
Olmesartan—Arthralgia—Paclitaxel—kidney cancer	0.000141	0.000469	CcSEcCtD
Olmesartan—Myalgia—Paclitaxel—kidney cancer	0.000141	0.000469	CcSEcCtD
Olmesartan—Mediastinal disorder—Capecitabine—kidney cancer	0.000141	0.000468	CcSEcCtD
Olmesartan—Anxiety—Paclitaxel—kidney cancer	0.00014	0.000468	CcSEcCtD
Olmesartan—Face oedema—Doxorubicin—kidney cancer	0.00014	0.000467	CcSEcCtD
Olmesartan—Decreased appetite—Gemcitabine—kidney cancer	0.00014	0.000467	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00014	0.000466	CcSEcCtD
Olmesartan—Arrhythmia—Capecitabine—kidney cancer	0.000139	0.000464	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000139	0.000464	CcSEcCtD
Olmesartan—Discomfort—Paclitaxel—kidney cancer	0.000139	0.000464	CcSEcCtD
Olmesartan—Fatigue—Gemcitabine—kidney cancer	0.000139	0.000463	CcSEcCtD
Olmesartan—Gastrointestinal pain—Vincristine—kidney cancer	0.000139	0.000463	CcSEcCtD
Olmesartan—Dizziness—Sorafenib—kidney cancer	0.000138	0.00046	CcSEcCtD
Olmesartan—Pain—Gemcitabine—kidney cancer	0.000138	0.000459	CcSEcCtD
Olmesartan—Constipation—Gemcitabine—kidney cancer	0.000138	0.000459	CcSEcCtD
Olmesartan—Nausea—Erlotinib—kidney cancer	0.000138	0.000459	CcSEcCtD
Olmesartan—Alopecia—Capecitabine—kidney cancer	0.000138	0.000459	CcSEcCtD
Olmesartan—Diarrhoea—Sunitinib—kidney cancer	0.000137	0.000458	CcSEcCtD
Olmesartan—Mental disorder—Capecitabine—kidney cancer	0.000137	0.000455	CcSEcCtD
Olmesartan—Asthenia—Dactinomycin—kidney cancer	0.000136	0.000455	CcSEcCtD
Olmesartan—Blood creatinine increased—Doxorubicin—kidney cancer	0.000136	0.000453	CcSEcCtD
Olmesartan—Malnutrition—Capecitabine—kidney cancer	0.000136	0.000452	CcSEcCtD
Olmesartan—Oedema—Paclitaxel—kidney cancer	0.000135	0.00045	CcSEcCtD
Olmesartan—Anaphylactic shock—Paclitaxel—kidney cancer	0.000135	0.00045	CcSEcCtD
Olmesartan—Body temperature increased—Vincristine—kidney cancer	0.000134	0.000448	CcSEcCtD
Olmesartan—Abdominal pain—Vincristine—kidney cancer	0.000134	0.000448	CcSEcCtD
Olmesartan—Infection—Paclitaxel—kidney cancer	0.000134	0.000447	CcSEcCtD
Olmesartan—Dizziness—Sunitinib—kidney cancer	0.000133	0.000443	CcSEcCtD
Olmesartan—Feeling abnormal—Gemcitabine—kidney cancer	0.000133	0.000443	CcSEcCtD
Olmesartan—Shock—Paclitaxel—kidney cancer	0.000133	0.000442	CcSEcCtD
Olmesartan—Vomiting—Sorafenib—kidney cancer	0.000133	0.000442	CcSEcCtD
Olmesartan—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000133	0.000442	CcSEcCtD
Olmesartan—Nervous system disorder—Paclitaxel—kidney cancer	0.000132	0.000441	CcSEcCtD
Olmesartan—Hypokalaemia—Doxorubicin—kidney cancer	0.000132	0.000441	CcSEcCtD
Olmesartan—Thrombocytopenia—Paclitaxel—kidney cancer	0.000132	0.00044	CcSEcCtD
Olmesartan—Tachycardia—Paclitaxel—kidney cancer	0.000132	0.000439	CcSEcCtD
Olmesartan—Rash—Sorafenib—kidney cancer	0.000132	0.000439	CcSEcCtD
Olmesartan—Dermatitis—Sorafenib—kidney cancer	0.000132	0.000438	CcSEcCtD
Olmesartan—Back pain—Capecitabine—kidney cancer	0.000131	0.000437	CcSEcCtD
Olmesartan—Skin disorder—Paclitaxel—kidney cancer	0.000131	0.000437	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000131	0.000436	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000131	0.000436	CcSEcCtD
Olmesartan—Headache—Sorafenib—kidney cancer	0.000131	0.000436	CcSEcCtD
Olmesartan—Muscle spasms—Capecitabine—kidney cancer	0.00013	0.000435	CcSEcCtD
Olmesartan—Hyperhidrosis—Paclitaxel—kidney cancer	0.00013	0.000435	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	0.00013	0.00841	CbGpPWpGaD
Olmesartan—Diarrhoea—Dactinomycin—kidney cancer	0.00013	0.000434	CcSEcCtD
Olmesartan—Nasopharyngitis—Doxorubicin—kidney cancer	0.00013	0.000433	CcSEcCtD
Olmesartan—AGTR1—Arf6 trafficking events—CTNNB1—kidney cancer	0.000129	0.00832	CbGpPWpGaD
Olmesartan—Anorexia—Paclitaxel—kidney cancer	0.000129	0.000429	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000128	0.0083	CbGpPWpGaD
Olmesartan—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000128	0.000427	CcSEcCtD
Olmesartan—Vision blurred—Capecitabine—kidney cancer	0.000128	0.000426	CcSEcCtD
Olmesartan—Vomiting—Sunitinib—kidney cancer	0.000128	0.000426	CcSEcCtD
Olmesartan—Body temperature increased—Gemcitabine—kidney cancer	0.000127	0.000425	CcSEcCtD
Olmesartan—Rash—Sunitinib—kidney cancer	0.000127	0.000422	CcSEcCtD
Olmesartan—Dermatitis—Sunitinib—kidney cancer	0.000127	0.000422	CcSEcCtD
Olmesartan—Hypotension—Paclitaxel—kidney cancer	0.000126	0.00042	CcSEcCtD
Olmesartan—Ill-defined disorder—Capecitabine—kidney cancer	0.000126	0.00042	CcSEcCtD
Olmesartan—Headache—Sunitinib—kidney cancer	0.000126	0.000419	CcSEcCtD
Olmesartan—Influenza—Doxorubicin—kidney cancer	0.000126	0.000418	CcSEcCtD
Olmesartan—Anaemia—Capecitabine—kidney cancer	0.000125	0.000418	CcSEcCtD
Olmesartan—Eosinophilia—Doxorubicin—kidney cancer	0.000124	0.000414	CcSEcCtD
Olmesartan—Nausea—Sorafenib—kidney cancer	0.000124	0.000413	CcSEcCtD
Olmesartan—Pancreatitis—Doxorubicin—kidney cancer	0.000123	0.00041	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000123	0.00041	CcSEcCtD
Olmesartan—Malaise—Capecitabine—kidney cancer	0.000122	0.000408	CcSEcCtD
Olmesartan—Angina pectoris—Doxorubicin—kidney cancer	0.000122	0.000408	CcSEcCtD
Olmesartan—Insomnia—Paclitaxel—kidney cancer	0.000122	0.000407	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—ANXA1—kidney cancer	0.000122	0.00788	CbGpPWpGaD
Olmesartan—Vertigo—Capecitabine—kidney cancer	0.000122	0.000406	CcSEcCtD
Olmesartan—Asthenia—Vincristine—kidney cancer	0.000122	0.000406	CcSEcCtD
Olmesartan—Syncope—Capecitabine—kidney cancer	0.000122	0.000406	CcSEcCtD
Olmesartan—Leukopenia—Capecitabine—kidney cancer	0.000121	0.000405	CcSEcCtD
Olmesartan—Vomiting—Dactinomycin—kidney cancer	0.000121	0.000403	CcSEcCtD
Olmesartan—Bronchitis—Doxorubicin—kidney cancer	0.000121	0.000402	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.00012	0.00778	CbGpPWpGaD
Olmesartan—Palpitations—Capecitabine—kidney cancer	0.00012	0.0004	CcSEcCtD
Olmesartan—Rash—Dactinomycin—kidney cancer	0.00012	0.0004	CcSEcCtD
Olmesartan—Nausea—Sunitinib—kidney cancer	0.000119	0.000398	CcSEcCtD
Olmesartan—Loss of consciousness—Capecitabine—kidney cancer	0.000119	0.000397	CcSEcCtD
Olmesartan—Pancytopenia—Doxorubicin—kidney cancer	0.000119	0.000397	CcSEcCtD
Olmesartan—Dyspepsia—Paclitaxel—kidney cancer	0.000119	0.000396	CcSEcCtD
Olmesartan—Cough—Capecitabine—kidney cancer	0.000118	0.000395	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—OR4C13—kidney cancer	0.000117	0.00759	CbGpPWpGaD
Olmesartan—Neutropenia—Doxorubicin—kidney cancer	0.000117	0.000391	CcSEcCtD
Olmesartan—Decreased appetite—Paclitaxel—kidney cancer	0.000117	0.000391	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000117	0.000389	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000117	0.000388	CcSEcCtD
Olmesartan—Fatigue—Paclitaxel—kidney cancer	0.000116	0.000388	CcSEcCtD
Olmesartan—Diarrhoea—Vincristine—kidney cancer	0.000116	0.000387	CcSEcCtD
Olmesartan—Asthenia—Gemcitabine—kidney cancer	0.000116	0.000385	CcSEcCtD
Olmesartan—Myalgia—Capecitabine—kidney cancer	0.000116	0.000385	CcSEcCtD
Olmesartan—Chest pain—Capecitabine—kidney cancer	0.000116	0.000385	CcSEcCtD
Olmesartan—Arthralgia—Capecitabine—kidney cancer	0.000116	0.000385	CcSEcCtD
Olmesartan—Constipation—Paclitaxel—kidney cancer	0.000115	0.000385	CcSEcCtD
Olmesartan—Pain—Paclitaxel—kidney cancer	0.000115	0.000385	CcSEcCtD
Olmesartan—Anxiety—Capecitabine—kidney cancer	0.000115	0.000384	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000115	0.000382	CcSEcCtD
Olmesartan—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000115	0.000382	CcSEcCtD
Olmesartan—Discomfort—Capecitabine—kidney cancer	0.000114	0.00038	CcSEcCtD
Olmesartan—Pruritus—Gemcitabine—kidney cancer	0.000114	0.00038	CcSEcCtD
Olmesartan—Hyperglycaemia—Doxorubicin—kidney cancer	0.000113	0.000377	CcSEcCtD
Olmesartan—Nausea—Dactinomycin—kidney cancer	0.000113	0.000376	CcSEcCtD
Olmesartan—Pneumonia—Doxorubicin—kidney cancer	0.000113	0.000375	CcSEcCtD
Olmesartan—Dizziness—Vincristine—kidney cancer	0.000112	0.000374	CcSEcCtD
Olmesartan—Infestation—Doxorubicin—kidney cancer	0.000112	0.000373	CcSEcCtD
Olmesartan—Infestation NOS—Doxorubicin—kidney cancer	0.000112	0.000373	CcSEcCtD
Olmesartan—Feeling abnormal—Paclitaxel—kidney cancer	0.000111	0.000371	CcSEcCtD
Olmesartan—Oedema—Capecitabine—kidney cancer	0.000111	0.000369	CcSEcCtD
Olmesartan—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00011	0.000368	CcSEcCtD
Olmesartan—Diarrhoea—Gemcitabine—kidney cancer	0.00011	0.000368	CcSEcCtD
Olmesartan—Renal failure—Doxorubicin—kidney cancer	0.00011	0.000367	CcSEcCtD
Olmesartan—Infection—Capecitabine—kidney cancer	0.00011	0.000367	CcSEcCtD
Olmesartan—Jaundice—Doxorubicin—kidney cancer	0.000109	0.000364	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	0.000109	0.00705	CbGpPWpGaD
Olmesartan—Shock—Capecitabine—kidney cancer	0.000109	0.000363	CcSEcCtD
Olmesartan—Urinary tract infection—Doxorubicin—kidney cancer	0.000109	0.000363	CcSEcCtD
Olmesartan—Nervous system disorder—Capecitabine—kidney cancer	0.000109	0.000362	CcSEcCtD
Olmesartan—Thrombocytopenia—Capecitabine—kidney cancer	0.000108	0.000361	CcSEcCtD
Olmesartan—Tachycardia—Capecitabine—kidney cancer	0.000108	0.00036	CcSEcCtD
Olmesartan—Vomiting—Vincristine—kidney cancer	0.000108	0.00036	CcSEcCtD
Olmesartan—Skin disorder—Capecitabine—kidney cancer	0.000108	0.000358	CcSEcCtD
Olmesartan—Urticaria—Paclitaxel—kidney cancer	0.000107	0.000357	CcSEcCtD
Olmesartan—Rash—Vincristine—kidney cancer	0.000107	0.000357	CcSEcCtD
Olmesartan—Hyperhidrosis—Capecitabine—kidney cancer	0.000107	0.000357	CcSEcCtD
Olmesartan—Dermatitis—Vincristine—kidney cancer	0.000107	0.000357	CcSEcCtD
Olmesartan—Haematuria—Doxorubicin—kidney cancer	0.000107	0.000356	CcSEcCtD
Olmesartan—Abdominal pain—Paclitaxel—kidney cancer	0.000107	0.000356	CcSEcCtD
Olmesartan—Body temperature increased—Paclitaxel—kidney cancer	0.000107	0.000356	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—OR4C13—kidney cancer	0.000107	0.00689	CbGpPWpGaD
Olmesartan—Headache—Vincristine—kidney cancer	0.000106	0.000355	CcSEcCtD
Olmesartan—Anorexia—Capecitabine—kidney cancer	0.000106	0.000352	CcSEcCtD
Olmesartan—Sinusitis—Doxorubicin—kidney cancer	0.000105	0.00035	CcSEcCtD
Olmesartan—Agranulocytosis—Doxorubicin—kidney cancer	0.000104	0.000348	CcSEcCtD
Olmesartan—Hypotension—Capecitabine—kidney cancer	0.000104	0.000345	CcSEcCtD
Olmesartan—Vomiting—Gemcitabine—kidney cancer	0.000103	0.000342	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000102	0.00661	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—kidney cancer	0.000102	0.00659	CbGpPWpGaD
Olmesartan—Rash—Gemcitabine—kidney cancer	0.000102	0.000339	CcSEcCtD
Olmesartan—Dermatitis—Gemcitabine—kidney cancer	0.000102	0.000338	CcSEcCtD
Olmesartan—Headache—Gemcitabine—kidney cancer	0.000101	0.000337	CcSEcCtD
Olmesartan—Nausea—Vincristine—kidney cancer	0.000101	0.000336	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000101	0.000336	CcSEcCtD
Olmesartan—Rhinitis—Doxorubicin—kidney cancer	0.000101	0.000336	CcSEcCtD
Olmesartan—Insomnia—Capecitabine—kidney cancer	0.0001	0.000334	CcSEcCtD
Olmesartan—Pharyngitis—Doxorubicin—kidney cancer	9.97e-05	0.000332	CcSEcCtD
Olmesartan—Urinary tract disorder—Doxorubicin—kidney cancer	9.93e-05	0.000331	CcSEcCtD
Olmesartan—Oedema peripheral—Doxorubicin—kidney cancer	9.9e-05	0.00033	CcSEcCtD
Olmesartan—Connective tissue disorder—Doxorubicin—kidney cancer	9.88e-05	0.000329	CcSEcCtD
Olmesartan—Urethral disorder—Doxorubicin—kidney cancer	9.85e-05	0.000328	CcSEcCtD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	9.75e-05	0.0063	CbGpPWpGaD
Olmesartan—Dyspepsia—Capecitabine—kidney cancer	9.75e-05	0.000325	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—kidney cancer	9.71e-05	0.00627	CbGpPWpGaD
Olmesartan—Asthenia—Paclitaxel—kidney cancer	9.68e-05	0.000323	CcSEcCtD
Olmesartan—Decreased appetite—Capecitabine—kidney cancer	9.63e-05	0.000321	CcSEcCtD
Olmesartan—Nausea—Gemcitabine—kidney cancer	9.58e-05	0.000319	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Capecitabine—kidney cancer	9.56e-05	0.000319	CcSEcCtD
Olmesartan—Fatigue—Capecitabine—kidney cancer	9.55e-05	0.000318	CcSEcCtD
Olmesartan—Pruritus—Paclitaxel—kidney cancer	9.55e-05	0.000318	CcSEcCtD
Olmesartan—Constipation—Capecitabine—kidney cancer	9.47e-05	0.000316	CcSEcCtD
Olmesartan—Pain—Capecitabine—kidney cancer	9.47e-05	0.000316	CcSEcCtD
Olmesartan—Diarrhoea—Paclitaxel—kidney cancer	9.24e-05	0.000308	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—RYR1—kidney cancer	9.19e-05	0.00594	CbGpPWpGaD
Olmesartan—Feeling abnormal—Capecitabine—kidney cancer	9.13e-05	0.000304	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—kidney cancer	9.12e-05	0.000304	CcSEcCtD
Olmesartan—Gastrointestinal pain—Capecitabine—kidney cancer	9.06e-05	0.000302	CcSEcCtD
Olmesartan—Mediastinal disorder—Doxorubicin—kidney cancer	9.06e-05	0.000302	CcSEcCtD
Olmesartan—Arrhythmia—Doxorubicin—kidney cancer	8.98e-05	0.000299	CcSEcCtD
Olmesartan—Dizziness—Paclitaxel—kidney cancer	8.93e-05	0.000297	CcSEcCtD
Olmesartan—Alopecia—Doxorubicin—kidney cancer	8.88e-05	0.000296	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—kidney cancer	8.81e-05	0.000293	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL2—kidney cancer	8.8e-05	0.00569	CbGpPWpGaD
Olmesartan—Urticaria—Capecitabine—kidney cancer	8.8e-05	0.000293	CcSEcCtD
Olmesartan—Abdominal pain—Capecitabine—kidney cancer	8.76e-05	0.000292	CcSEcCtD
Olmesartan—Body temperature increased—Capecitabine—kidney cancer	8.76e-05	0.000292	CcSEcCtD
Olmesartan—Malnutrition—Doxorubicin—kidney cancer	8.75e-05	0.000292	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SLC5A5—kidney cancer	8.69e-05	0.00561	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—RYR1—kidney cancer	8.63e-05	0.00557	CbGpPWpGaD
Olmesartan—Vomiting—Paclitaxel—kidney cancer	8.58e-05	0.000286	CcSEcCtD
Olmesartan—Rash—Paclitaxel—kidney cancer	8.51e-05	0.000284	CcSEcCtD
Olmesartan—Dermatitis—Paclitaxel—kidney cancer	8.5e-05	0.000283	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—kidney cancer	8.46e-05	0.000282	CcSEcCtD
Olmesartan—Headache—Paclitaxel—kidney cancer	8.46e-05	0.000282	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—kidney cancer	8.42e-05	0.00544	CbGpPWpGaD
Olmesartan—Muscle spasms—Doxorubicin—kidney cancer	8.41e-05	0.00028	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SLC2A1—kidney cancer	8.39e-05	0.00542	CbGpPWpGaD
Olmesartan—Vision blurred—Doxorubicin—kidney cancer	8.25e-05	0.000275	CcSEcCtD
Olmesartan—Ill-defined disorder—Doxorubicin—kidney cancer	8.12e-05	0.00027	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—kidney cancer	8.09e-05	0.000269	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	8.08e-05	0.00522	CbGpPWpGaD
Olmesartan—Agitation—Doxorubicin—kidney cancer	8.04e-05	0.000268	CcSEcCtD
Olmesartan—Nausea—Paclitaxel—kidney cancer	8.02e-05	0.000267	CcSEcCtD
Olmesartan—Asthenia—Capecitabine—kidney cancer	7.95e-05	0.000265	CcSEcCtD
Olmesartan—Malaise—Doxorubicin—kidney cancer	7.89e-05	0.000263	CcSEcCtD
Olmesartan—Vertigo—Doxorubicin—kidney cancer	7.86e-05	0.000262	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—kidney cancer	7.85e-05	0.000261	CcSEcCtD
Olmesartan—Pruritus—Capecitabine—kidney cancer	7.84e-05	0.000261	CcSEcCtD
Olmesartan—Leukopenia—Doxorubicin—kidney cancer	7.83e-05	0.000261	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—EGR1—kidney cancer	7.79e-05	0.00503	CbGpPWpGaD
Olmesartan—Palpitations—Doxorubicin—kidney cancer	7.73e-05	0.000258	CcSEcCtD
Olmesartan—Loss of consciousness—Doxorubicin—kidney cancer	7.69e-05	0.000256	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	7.66e-05	0.00495	CbGpPWpGaD
Olmesartan—Cough—Doxorubicin—kidney cancer	7.63e-05	0.000254	CcSEcCtD
Olmesartan—Diarrhoea—Capecitabine—kidney cancer	7.58e-05	0.000253	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—kidney cancer	7.48e-05	0.00483	CbGpPWpGaD
Olmesartan—Myalgia—Doxorubicin—kidney cancer	7.45e-05	0.000248	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—kidney cancer	7.45e-05	0.000248	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—kidney cancer	7.45e-05	0.000248	CcSEcCtD
Olmesartan—Anxiety—Doxorubicin—kidney cancer	7.42e-05	0.000247	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.4e-05	0.000246	CcSEcCtD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	7.39e-05	0.00478	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ANXA2—kidney cancer	7.38e-05	0.00477	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	7.38e-05	0.00477	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ATP7B—kidney cancer	7.38e-05	0.00477	CbGpPWpGaD
Olmesartan—Discomfort—Doxorubicin—kidney cancer	7.36e-05	0.000245	CcSEcCtD
Olmesartan—Dizziness—Capecitabine—kidney cancer	7.33e-05	0.000244	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—kidney cancer	7.14e-05	0.000238	CcSEcCtD
Olmesartan—Anaphylactic shock—Doxorubicin—kidney cancer	7.14e-05	0.000238	CcSEcCtD
Olmesartan—Infection—Doxorubicin—kidney cancer	7.09e-05	0.000236	CcSEcCtD
Olmesartan—Vomiting—Capecitabine—kidney cancer	7.04e-05	0.000235	CcSEcCtD
Olmesartan—Shock—Doxorubicin—kidney cancer	7.03e-05	0.000234	CcSEcCtD
Olmesartan—Nervous system disorder—Doxorubicin—kidney cancer	7e-05	0.000233	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTP1—kidney cancer	7e-05	0.00452	CbGpPWpGaD
Olmesartan—Thrombocytopenia—Doxorubicin—kidney cancer	6.99e-05	0.000233	CcSEcCtD
Olmesartan—Rash—Capecitabine—kidney cancer	6.98e-05	0.000233	CcSEcCtD
Olmesartan—Dermatitis—Capecitabine—kidney cancer	6.98e-05	0.000232	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—kidney cancer	6.97e-05	0.000232	CcSEcCtD
Olmesartan—Headache—Capecitabine—kidney cancer	6.94e-05	0.000231	CcSEcCtD
Olmesartan—Skin disorder—Doxorubicin—kidney cancer	6.94e-05	0.000231	CcSEcCtD
Olmesartan—Hyperhidrosis—Doxorubicin—kidney cancer	6.9e-05	0.00023	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.88e-05	0.00444	CbGpPWpGaD
Olmesartan—Anorexia—Doxorubicin—kidney cancer	6.81e-05	0.000227	CcSEcCtD
Olmesartan—Hypotension—Doxorubicin—kidney cancer	6.67e-05	0.000222	CcSEcCtD
Olmesartan—Nausea—Capecitabine—kidney cancer	6.58e-05	0.000219	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—ACY1—kidney cancer	6.58e-05	0.00425	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.51e-05	0.000217	CcSEcCtD
Olmesartan—Insomnia—Doxorubicin—kidney cancer	6.46e-05	0.000215	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTM1—kidney cancer	6.43e-05	0.00416	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—OR4C13—kidney cancer	6.3e-05	0.00407	CbGpPWpGaD
Olmesartan—Dyspepsia—Doxorubicin—kidney cancer	6.29e-05	0.000209	CcSEcCtD
Olmesartan—Decreased appetite—Doxorubicin—kidney cancer	6.21e-05	0.000207	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.16e-05	0.000205	CcSEcCtD
Olmesartan—Fatigue—Doxorubicin—kidney cancer	6.16e-05	0.000205	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—ANXA1—kidney cancer	6.15e-05	0.00397	CbGpPWpGaD
Olmesartan—Pain—Doxorubicin—kidney cancer	6.11e-05	0.000203	CcSEcCtD
Olmesartan—Constipation—Doxorubicin—kidney cancer	6.11e-05	0.000203	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—POMC—kidney cancer	5.9e-05	0.00381	CbGpPWpGaD
Olmesartan—Feeling abnormal—Doxorubicin—kidney cancer	5.88e-05	0.000196	CcSEcCtD
Olmesartan—Gastrointestinal pain—Doxorubicin—kidney cancer	5.84e-05	0.000195	CcSEcCtD
Olmesartan—Urticaria—Doxorubicin—kidney cancer	5.67e-05	0.000189	CcSEcCtD
Olmesartan—Body temperature increased—Doxorubicin—kidney cancer	5.64e-05	0.000188	CcSEcCtD
Olmesartan—Abdominal pain—Doxorubicin—kidney cancer	5.64e-05	0.000188	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.61e-05	0.00362	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PDHB—kidney cancer	5.59e-05	0.00361	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LATS1—kidney cancer	5.36e-05	0.00346	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ANXA2—kidney cancer	5.28e-05	0.00341	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	5.28e-05	0.00341	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ATP7B—kidney cancer	5.28e-05	0.00341	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CCBL1—kidney cancer	5.26e-05	0.0034	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	5.14e-05	0.00332	CbGpPWpGaD
Olmesartan—Asthenia—Doxorubicin—kidney cancer	5.12e-05	0.000171	CcSEcCtD
Olmesartan—Pruritus—Doxorubicin—kidney cancer	5.05e-05	0.000168	CcSEcCtD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	4.97e-05	0.00321	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	4.96e-05	0.0032	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ATP7B—kidney cancer	4.96e-05	0.0032	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ANXA2—kidney cancer	4.96e-05	0.0032	CbGpPWpGaD
Olmesartan—Diarrhoea—Doxorubicin—kidney cancer	4.89e-05	0.000163	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—AKAP13—kidney cancer	4.88e-05	0.00315	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.75e-05	0.00307	CbGpPWpGaD
Olmesartan—Dizziness—Doxorubicin—kidney cancer	4.72e-05	0.000157	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—PPAT—kidney cancer	4.56e-05	0.00295	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GLIPR1—kidney cancer	4.56e-05	0.00295	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AMER1—kidney cancer	4.56e-05	0.00294	CbGpPWpGaD
Olmesartan—Vomiting—Doxorubicin—kidney cancer	4.54e-05	0.000151	CcSEcCtD
Olmesartan—Rash—Doxorubicin—kidney cancer	4.5e-05	0.00015	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.5e-05	0.00291	CbGpPWpGaD
Olmesartan—Dermatitis—Doxorubicin—kidney cancer	4.5e-05	0.00015	CcSEcCtD
Olmesartan—Headache—Doxorubicin—kidney cancer	4.47e-05	0.000149	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.46e-05	0.00288	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKAP13—kidney cancer	4.43e-05	0.00286	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ACY1—kidney cancer	4.42e-05	0.00285	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	4.41e-05	0.00285	CbGpPWpGaD
Olmesartan—Nausea—Doxorubicin—kidney cancer	4.24e-05	0.000141	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—FH—kidney cancer	4.24e-05	0.00274	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—APRT—kidney cancer	4.24e-05	0.00274	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ITPR2—kidney cancer	4.15e-05	0.00268	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.14e-05	0.00268	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GPC3—kidney cancer	3.98e-05	0.00257	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	3.96e-05	0.00256	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.89e-05	0.00251	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CA2—kidney cancer	3.88e-05	0.0025	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CER1—kidney cancer	3.82e-05	0.00247	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GPC3—kidney cancer	3.82e-05	0.00247	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALAD—kidney cancer	3.78e-05	0.00244	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.77e-05	0.00243	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ITPR2—kidney cancer	3.77e-05	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.76e-05	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PDHB—kidney cancer	3.76e-05	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ST3GAL2—kidney cancer	3.69e-05	0.00238	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALDH1A1—kidney cancer	3.6e-05	0.00233	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CCBL1—kidney cancer	3.53e-05	0.00228	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ANXA1—kidney cancer	3.48e-05	0.00225	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PGK1—kidney cancer	3.45e-05	0.00223	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC5A3—kidney cancer	3.45e-05	0.00223	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—LDHB—kidney cancer	3.39e-05	0.00219	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SFRP2—kidney cancer	3.25e-05	0.0021	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	3.19e-05	0.00206	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	3.18e-05	0.00205	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ANXA1—kidney cancer	3.16e-05	0.00204	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GLIPR1—kidney cancer	3.06e-05	0.00198	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPAT—kidney cancer	3.06e-05	0.00198	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.02e-05	0.00195	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	3.02e-05	0.00195	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—POMC—kidney cancer	3.01e-05	0.00195	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.99e-05	0.00193	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.97e-05	0.00192	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CA9—kidney cancer	2.94e-05	0.0019	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—PIK3CA—kidney cancer	2.93e-05	0.00189	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.87e-05	0.00185	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	2.85e-05	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—APRT—kidney cancer	2.85e-05	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—FH—kidney cancer	2.85e-05	0.00184	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.78e-05	0.0018	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.78e-05	0.0018	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.69e-05	0.00174	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GPC3—kidney cancer	2.68e-05	0.00173	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	2.62e-05	0.00169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKAP13—kidney cancer	2.62e-05	0.00169	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CASP2—kidney cancer	2.62e-05	0.00169	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.61e-05	0.00169	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA2—kidney cancer	2.6e-05	0.00168	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALAD—kidney cancer	2.54e-05	0.00164	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.52e-05	0.00163	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CRABP1—kidney cancer	2.5e-05	0.00161	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ST3GAL2—kidney cancer	2.48e-05	0.0016	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALDH1A1—kidney cancer	2.42e-05	0.00156	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GRB7—kidney cancer	2.39e-05	0.00155	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ITPR2—kidney cancer	2.32e-05	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PGK1—kidney cancer	2.32e-05	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC5A3—kidney cancer	2.32e-05	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—LDHB—kidney cancer	2.28e-05	0.00147	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ITPR2—kidney cancer	2.23e-05	0.00144	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.14e-05	0.00138	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.12e-05	0.00137	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTT1—kidney cancer	2.12e-05	0.00137	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ACHE—kidney cancer	2.12e-05	0.00137	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CTNNA1—kidney cancer	2.02e-05	0.0013	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EIF4EBP1—kidney cancer	2.01e-05	0.0013	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HSPB1—kidney cancer	2.01e-05	0.0013	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SCARB1—kidney cancer	2e-05	0.0013	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.99e-05	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS1—kidney cancer	1.98e-05	0.00128	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CA9—kidney cancer	1.97e-05	0.00128	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSMD7—kidney cancer	1.95e-05	0.00126	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.93e-05	0.00125	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ANXA1—kidney cancer	1.86e-05	0.0012	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TSC1—kidney cancer	1.86e-05	0.0012	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSMD7—kidney cancer	1.86e-05	0.0012	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—BCHE—kidney cancer	1.84e-05	0.00119	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC5A5—kidney cancer	1.82e-05	0.00118	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FLT1—kidney cancer	1.81e-05	0.00117	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC2A1—kidney cancer	1.76e-05	0.00114	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.71e-05	0.0011	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—POMC—kidney cancer	1.7e-05	0.0011	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—RAF1—kidney cancer	1.68e-05	0.00108	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CRABP1—kidney cancer	1.68e-05	0.00108	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PAK1—kidney cancer	1.67e-05	0.00108	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUNB—kidney cancer	1.67e-05	0.00108	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ITPR2—kidney cancer	1.56e-05	0.00101	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—POMC—kidney cancer	1.55e-05	0.000999	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.49e-05	0.000962	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTP1—kidney cancer	1.47e-05	0.000948	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.44e-05	0.000929	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTT1—kidney cancer	1.42e-05	0.000919	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ACHE—kidney cancer	1.42e-05	0.000919	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ABCB1—kidney cancer	1.39e-05	0.000898	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF2—kidney cancer	1.37e-05	0.000884	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN2B—kidney cancer	1.36e-05	0.00088	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTM1—kidney cancer	1.35e-05	0.000871	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SCARB1—kidney cancer	1.35e-05	0.00087	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS1—kidney cancer	1.33e-05	0.000861	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF1R—kidney cancer	1.32e-05	0.000855	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSMD7—kidney cancer	1.31e-05	0.000845	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1A1—kidney cancer	1.28e-05	0.000826	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—RAF1—kidney cancer	1.28e-05	0.000824	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL2—kidney cancer	1.26e-05	0.000813	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—BCHE—kidney cancer	1.24e-05	0.000801	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC5A5—kidney cancer	1.22e-05	0.000791	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—RAF1—kidney cancer	1.2e-05	0.000776	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC2A1—kidney cancer	1.18e-05	0.000764	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.15e-05	0.000741	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL2—kidney cancer	1.14e-05	0.000739	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.13e-05	0.000728	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HIF1A—kidney cancer	1.09e-05	0.000704	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TSC2—kidney cancer	1.09e-05	0.000702	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.05e-05	0.000679	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KDR—kidney cancer	1.04e-05	0.000673	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1e-05	0.000646	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTP1—kidney cancer	9.86e-06	0.000637	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KIT—kidney cancer	9.6e-06	0.00062	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—APC—kidney cancer	9.6e-06	0.00062	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—POMC—kidney cancer	9.53e-06	0.000616	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ABCB1—kidney cancer	9.34e-06	0.000603	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—MAPK3—kidney cancer	9.19e-06	0.000594	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—POMC—kidney cancer	9.14e-06	0.00059	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTM1—kidney cancer	9.06e-06	0.000585	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BRAF—kidney cancer	9.02e-06	0.000583	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—MAPK1—kidney cancer	8.75e-06	0.000565	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1A1—kidney cancer	8.59e-06	0.000555	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CA—kidney cancer	8.36e-06	0.00054	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—KRAS—kidney cancer	8.26e-06	0.000534	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS2—kidney cancer	7.6e-06	0.000491	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CA—kidney cancer	7.59e-06	0.00049	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RAF1—kidney cancer	7.53e-06	0.000487	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RELA—kidney cancer	7.5e-06	0.000485	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ERBB2—kidney cancer	7.45e-06	0.000481	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MTOR—kidney cancer	7.35e-06	0.000475	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.06e-06	0.000456	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1B—kidney cancer	6.9e-06	0.000446	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2—kidney cancer	6.75e-06	0.000436	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTEN—kidney cancer	6.63e-06	0.000428	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCND1—kidney cancer	6.58e-06	0.000425	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUN—kidney cancer	6.57e-06	0.000424	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CTNNB1—kidney cancer	6.52e-06	0.000421	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—POMC—kidney cancer	6.41e-06	0.000414	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTEN—kidney cancer	6.35e-06	0.000411	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—kidney cancer	5.74e-06	0.000371	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK3—kidney cancer	5.43e-06	0.000351	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—kidney cancer	5.28e-06	0.000341	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK1—kidney cancer	5.17e-06	0.000334	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS2—kidney cancer	5.11e-06	0.00033	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KRAS—kidney cancer	4.88e-06	0.000315	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CA—kidney cancer	4.68e-06	0.000302	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CA—kidney cancer	4.48e-06	0.00029	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTEN—kidney cancer	4.46e-06	0.000288	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—kidney cancer	4.34e-06	0.00028	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CA—kidney cancer	3.14e-06	0.000203	CbGpPWpGaD
